XORTX Therapeutics Inc. (XRTX )

Currency in USD Disclaimer
$1.87 +$0.35 (23.03%)
Closed 10/15/2024
$1.51
$2.51
$1.09
$67.72

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol XRTX
  • Company XORTX Therapeutics Inc.
  • Price $1.87
  • Changes Percentage 23.03
  • Change 0.35
  • Day Low $1.51
  • Day High $2.51
  • Year High $67.72
  • Year Low $1.09
  • Market Cap $5,429,676
  • Price Avg 50 EMA (D) $1.66
  • Price Avg 200 EMA (D) $2.44
  • Exchange NASDAQ
  • Volume 1,552,798
  • Average Volume 2,821,062
  • Open $1.52
  • Previous Close $1.52
  • EPS -0.37
  • PE -5.05
  • Earnings Announcement 2024-11-12 21:00:00
  • Shares Outstanding $2,903,570

Company brief: XORTX THERAPEUTICS INC. (XRTX )

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

XRTX Corporation News

Income Statement